Abits
ABTS
Digihost Technology
DGHI
Argo Blockchain
ARBK
FRMO CORP
FRMO
The9 Ltd
NCTY
US Stock MarketDetailed Quotes
ORKA Oruka Therapeutics
- 11.470
- -0.420-3.53%
Close Mar 18 16:00 ET
- 11.470
- 0.0000.00%
Post 20:01 ET
429.44MMarket Cap-30.18P/E (TTM)
11.940High11.440Low378.91KVolume11.690Open11.890Pre Close4.40MTurnover1.62%Turnover RatioLossP/E (Static)37.44MShares33.00052wk High1.13P/B268.46MFloat Cap9.44052wk Low--Dividend TTM23.41MShs Float40838092.445Historical High--Div YieldTTM4.21%Amplitude9.440Historical Low11.614Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Oruka Therapeutics Stock Forum
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration
Equivalent potency to risankizumab with similar binding affinity and epitope demonstrated in several preclinical assays
MENLO PARK, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc...
looking forward to see how this performs
No comment yet